StemCell Therapy

Few people think much about web accessibility. Even fewer people understand it, and without understanding there wont be empathy or change. However, a string of high-profile class action lawsuits in 2019, like the one against Beyonces management company, brought the issue to light and I expect well see a lot more companies prioritizing web accessibility in 2020.

At the same time, the US and many European countries are more rigorously enforcing their by-laws applying to free content accessibility. Companies will no longer be able to afford to ignore this issue.

Its no surprise that visually impaired people are demanding better access. Populated with Instagram stories and online stores that display 360-degree, high-definition product images and video, the web has become a visual public space. That puts many people at an unnecessary disadvantage.

Its not only lawsuits driving demand for greater visual access, but the growing problem of poor vision. According to the World Health Organization (WHO), around 1.3 billion people have some visual impairment, such as low vision, color blindness, and (partial)blindness. Thats nearly 20 percent of the global population including your website visitors who struggle with accessibility.

Ill be the first to accept that the US is more lawsuit-happy than most. Maybe you live in another country, with a different legal culture and dont think you need to worry about accessibility. Thats the wrong mindset.

As a frontend developer, I do care about web accessibility; its my responsibility. I dont want visitors just to have access. I want them to have the best possible experience. Lets take a closer look now at some of the different types of visual impairments people have and how to address them on a site.

Light sensitivity is a very common issue, especially for people who sit in front of computer screens all day. Light-sensitive people can find it hard, painful, or even impossible to read and concentrate under bright lights, on bright screens, or on web pages where bright colors are combined.

This is why most developers like me switch to dark themes in their dev tools, IDE, or their OS (if it has one). Its also why popular apps like Twitter, Google, Facebook Messenger, and recently iOS, provide Dark Mode.

One difficulty is that theres no one standard for light sensitivity. It varies by person and setting, so its impossible to devise one configuration set that works for all light-sensitive people.

Offer Dark Mode or a Light Theme for your users and allow them to set the brightness, essentially letting them decide for themselves.

There are several approaches to achieve this, depending on your technology stack and browser support. A straightforward way is to combine a CSS variable and the CSS invert method: filter: invert().

By defining invert(1), the browser inverts all colors available in your apps to the exact opposite matching colors.

This filter effect also applies to all images within the app. You might want to add some code to make sure colors are reserved even in inverted mode (dark or light).

Warning: filter is still not supported in IE. If IE support is critical for your app, consider using other approach such as CSS-in-JS (styled components for Vue or for React).

Contrast sensitivity occurs where people struggle to read text that is placed over images and videos. This happens when white text is placed on a light background, black text is placed on a dark background, or text is placed on a visually busy background.

Unlike light sensitivity, contrast sensitivity issues are easy to identify. Popular browsers including Chrome and Firefox now include a contrast score check in their dev tools, which flag any page sections that arent visible enough. You shouldnt rely solely on these tools, however, because the automatic scores are not always 100 percent accurate.

To address contrast sensitivity fully, refer to the Web Content Accessibility Guidelines (WCAG). It states that text, or images of text, must have a contrast ratio of at least 4.5:1. Exceptions are large text (where its 3:1), invisible, and decorative text and logotypes, where the text is part of a brand name.

To summarize some of the main points:

To ensure your website passes the contrast test, check out this free Contrast Checker tool by WebAIM.

Color blindness (or color vision deficiency) makes it difficult (or impossible) for affected people to identify or distinguish between specific colors.

Imagine a colorblind person visits an online store to buy a red t-shirt and sees only green ones. How would this visitor know which ones to buy?

In some cases it will be impossible to adapt an image to appear correctly for someone with color vision deficiency. For these, the options are to either provide chat/live support or text prompts (or, ideally, both).

To provide text prompts, we add the name of the color as text to images using the alt attribute. So instead of saying that an image is a t-shirt, we would explicitly state that it is a red t-shirt. The more specific, the better. Yellow is somewhat helpful, but mustard yellow is much more descriptive.

This will involve some light coding, or you can use one of the image management tools on the market that help automate this process.

Another option is to provide a unique pattern to represent each different color on your webpage. The standard approaches are not straightforward either designers need to manually code something or use image editing software like Photoshop or Gimp to create an extra resource for each colorblind case.

The free version of my companys own software includes a transformation e_assist_colorblind effect to make this process easier. For example, you can add stripes to highlight the difference between hot (red) and cold (green) colors.

Hopefully this has given you some ideas for how to address the most common issues around visual accessibility. By focusing on this important issue, youll not just avoid litigation, but youll attract more site visitors, raise engagement, and potentially boost revenue as well.

Published January 3, 2020 08:00 UTC

More here:
Visual accessibility will be a priority in 2020 heres how to adapt your site - The Next Web

(Photo : cdn.britannica.com)Improving the way to accessing technology is important for PWD and non-PWDS too. Creating interfaces that are customizable and adaptive for any kind of use will be a shock as to how well it adapts.

Everyone is surrounded by technology andaccessing technologyis important just like breathing. The speed of how much it developed is blinding, with several options for how to access it. This translates to convenience and assistive technology, enables those with disabilities still need help to use the internet.So, making access possible through more assistive technology should be done. If only to encourage more use, whether able or disabled.

In response to the needed of those, with a limitation for ready access to technology like the visual, hearing, and physical incapacity too. This list of adaptive access has made the internet more accessible than ever. There is one gap to breached, which is different cognitive functions that should be developed later on. In 2020, hopes are high to bridge this gap sooner than expected.

Blindness is not a hindrance for access if the interface is based onsound access that the blind personcan hear. It is a difference for those who do not have hearing, which makes it hard to translate sound instead. These problems of deafness and blindness should be studied and improve information access for these people.

It should not be neglected that even normal people are subject to having a hard time, interacting with interfaces for real too. Things were simple before just a dial or a button, that is it. Now complex digital is the in thing, some are plainly just as disabled from this. Not all are tech-savvy, and the majority would simply go for less complex. Technology is good, but if it alienates the users, there is something wrong.

Solving this conundrum can be done in two ways, and one is coming soon with another in development. Some technologies will benefit PWDS but are good only because the PWD needs the tech. But, anyone who can access the tech fine will find it hard to use it. It is a give and go for tech customized for PWDS and non-PWDS.

One of these assistive techs isMorphicthat is an OS extension that customizes a computer, to the specs of the unique user. For example, it fixes the appearance of the desktop to help the PWD or non-PWD navigate the screen. This is very convenient for everyone and makes thing automatic for the user too. Everything is so intuitive that it even falls back to the default on its own. Technology like this is very easy to use and simplifies access without complex actions,

For the long-term improvement for internet access, that would mean aa lot of innovation from tech companies producing smart devices. Instead of making their own versions (tech companies), it is better to have standard interface for normal users. Then, third parties will build the application from ground up to let PWDS use computers too.

One example of these user-adaptive apps that can be made to create customized interfaces for both. This is shocking to everyone as computers have the benefit of easier use. Not all tech producers will give away their tech so freely, which is another problem. So, this is a problem that needs solutions to make it feasible.

Getting the simplest way toaccessing technologyis a must, and expanding access will make great strides for any use. Nothing ever stays the same and more ways to access a computer, should be shocking for everyone concerned.

Related Article: The next decade will reshape how we think of technology accessibility

Read more from the original source:
Accessing Technology Is About to Change and It Will Be Shocking for Everyone - Science Times

Our politics, and the news cycle, dwell too much on crises and criticism.

Lets use New Years Eve as a moment to balance that, as we reflect on some good things that happened in 2019.

The largest hydroelectric project in the entire continent of Africa, the Grand Ethiopian Renaissance Dam, will continue to completion.

In November, the U.S. invited representatives of Ethiopia and the two downstream users of water from the Blue Nile, Sudan and Egypt, to Washington, to reach an agreement on how quickly the reservoir behind the dam would be filled and how the electricity produced by the dam would be shared.

A deadline for an agreement was set for Jan. 15, with arbitration agreed to for any remaining differences. Diplomatic tensions had undermined progress since 2011, with some Egyptian politicians even threatening to bomb the dam during construction.

The resolution of this dispute will allow for the electrification of huge parts of Ethiopia, Sudan and even Egypt, that lagged behind the economic development of the rest of the region. This progress was made possible by U.S. diplomatic pressure on Egypt and new leadership in both Ethiopia and Sudan.

Life expectancy in the world continues to improve, adding another three months in 2019. This small, if steady progress, continues an astounding record of improvement since 1950, when average world life expectancy was 45 years. Today, it is 73 years.

The percentage of children surviving past their first year improved during 2019, exceeding 97%, worldwide, for the first time in human history.

The Center for Infectious Disease Research and Policy at the University of Minnesota announced that Type 3 polio was eradicated from the world in October 2019. Type 2 was eradicated in 2015. Only one type of wild polio virus still remains in the world, in Afghanistan and Pakistan.

Along with the U.S. and other donor nations, researchers, and dedicated public health workers of many countries, the long-standing generosity and energetic devotion of Rotary International should be recognized in this tremendous achievement.

Another service organization, the Lions, deserve thanks for their persistence in the fight against blindness around the world. An international pharmaceutical company, Merck & Co., donates the medicine to treat river-blindness, an affliction that is one of the two largest causes of preventable loss of sight.

The Carter Center, founded by former President Jimmy Carter, has coordinated the delivery of these medications throughout Latin America and Africa. River-blindness is now effectively gone from Latin America. In August, world health authorities predicted Uganda would be free of this scourge imminently.

The magazine Business Insider recently reported on major achievements in space exploration during 2019.

Among the most remarkable this year are the first photograph of a black hole, the launching of a commercial spaceship to carry human passengers (SpaceX), the discovery of seismic activity on Mars, the departure of Voyager 2 from our solar system bound for inter-stellar space with much more sophisticated equipment than its predecessor Voyager 1 and the first landing on the far side of the moon. The latter event was achieved by China.

Focusing on the U.S., Americans returned to the workforce in a flood not observed since June 2013. Labor force participation is a key indicator of both future economic growth and of optimism about that growth.

As more Americans believe job opportunities will be permanent, they have started looking for jobs again, and, in great measure, finding them.

Real average earnings grew throughout 2019 in the U.S. economy. On both an hourly and a weekly basis, wages outpaced the cost of living, resulting in a growth in workers take-home pay every month this year. (That had not happened since 2016.)

The value of output per American worker rose in every quarter of last year, continuing an unbroken trend of growth since the third quarter of 2016.

It has been a wonderful year!

Tom Campbell teaches economics, law and political science at Chapman University. He is the interim chairman of a new political party, the Common Sense Party, which he is helping to form in California.

Read the original post:
Celebrating the good things that happened in 2019: Tom Campbell - The Whittier Daily News

Ice blocks, bound by rope and hanging from wooden beams, drip into ceramic bowls. With underwater microphones placed in the bowls, the trickling sound of the water dripping is amplified. It is a musicality of drops that you hear as you walk into the dimly lit, cool space at Sharjah Art Foundations Bait Obaid Al Shamsi. The notes resonate, full and expansive, in the restored creekside Emirati house complex; so much so that most of those who attended the opening of the second Sharjapan exhibition, Inter-Resonance: Inter-Organics Japanese Performance and Sound Art, last month, closed their eyes to be fully enveloped by the watery timbre.

The installation, In Curved Water, is one part of the show, organised by Sharjah Art Foundation, which runs until Saturday, February 15.

The exhibition focuses on bringing traditional Japanese practices and technology to the emirate. The water bowls installation is one of many in the historic Bait Al Shamsi venue, which also includes automated xylophones, magnet-driven bells, musical compasses and floor-strewn lightbulbs. Stand at the centre of the exhibition and youll hear the faint chimes, droplets and sizzles at random from each direction. Japanese artist Tomoko Sauvage spent 10 years developing her electro-aquatic instrument. Porcelain bowls, water drops, bubbles and hydrophonic feedback are its main components. Sauvage decided to develop the water bowls after attending an Anayampatti Ganesan concert in 2006. The musical virtuoso plays the Jalatharangam, the traditional Carnatic instrument made up of water-filled porcelain bowls.

Ive been experimenting with musical sounds since for ever, Sauvage, who has been based in France for the past 16 years, tells The National. I started working on the water bowls after seeing Ganesan perform. I went home and started hitting china bowls with chopsticks in my kitchen. The water bowls started taking form after I had the idea of using hydrophones.

Sauvages In Curved Water is a direct statement on the environment. The ice blocks are meant to allude to the glaciers melting as a result of climate change. Sauvage says that most people employ an out-of-sight, out-of-mind stance when it comes to environmental issues.

My musical experimentation is grounded in live-performance-based practices that investigate the improvisation and interaction with the environment, she says, adding that she hopes the installation will bridge the distance between the melting glaciers and the listener, making them feel as if they are bearing witness, in real time, to climate change. In this context, the meditative watery music becomes heavy with an ominously pressing message.

Though the water drops in Sauvages installation are randomly timed, the artist uses the electro-aquatic instrument in deliberately arranged live performances. Her 2007 album Musique Hydromantique exclusively features the instrument, and though it is comprised of only three tracks, it runs for more than 40 minutes.

Sharjapan is part of a four-year agreement between the Sharjah Art Foundation and curator Yuko Hasegawa. Last years exhibition, The Poetics of Space, focused on Japanese book design from the early 20th century to present day. This year, the focus is on performance art, sound-based installations and new technologies and traditional Japanese practices that explore the interactions between nature, technology and human life.

The exhibition comprises installations at Bait Obaid Al Shamsi and five performances that take place in venues across Sharjah. These feature a variety of art forms, including dance, music and literature. In addition to Sauvage, the participating artists are Eitetsu Hayashi, Yuko Mohri, Mirai Moriyama, Keiichiro Shibuya and Min Tanaka.

We wanted to bring a varied set of Japanese performances to this years exhibition, not just the well-known Kabuki theatre, says Hasegawa, who is also artistic director of the Museum of Contemporary Art in Tokyo. There are Sauvages water bowls, which allow people to visualise the looming threat of climate change; Eitetsu Hayashi, who will perform traditional Japanese taiko drumming in his pioneering style; and Min Tanaka, who will present an improvised dance piece that challenges the conventions of modern dance and questions the role of dance in contemporary society.

The dance pieces are inspired by the Japanese art of Butoh. Established after the Second World War, Butoh rebels directly against western styles of dance, with most of the moves carried out on the ground. It has an aggressive style to it, says Hasegawa. The movements are slow and unlike the western techniques of dance. The avant-garde dance aims to rebel against western influence.

The opening performance at this years Sharjapan was a movement piece by Moriyama. The Japanese actor, who began his dance training at five years old, brought a theatrical reading of Jose Saramagos Blindness to the Sharjah Institute of Theatrical Arts. The performance was called Consideration of the Invisible / Visible.

Directed to wear an earphone in one ear, members of the audience were seated on the stage, some two metres from Moriyama. The actor began his performance centre stage, reading the opening passage of the Nobel prize-winner Saramagos novel from an iPad. The story revolves around an unexplained mass epidemic of blindness afflicting nearly everyone in an unnamed city, and the chaos that follows.

With flickering lights, fragmented texts and movements, Moriyama invited audiences to take part in the plot. The performance seems to allude to modern social issues such as depression and loneliness. Uncomfortable at times and serene at others, Moriyamas performance was deeply contemplative. Though this performance has now elapsed, the schedule of events promises to be equally as exciting.

Sharjapan: Inter-Resonance: Inter-Organics Japanese Performance and Sound Art runs until Saturday, February 15. Shows take place in various locations across Sharjah

Updated: January 4, 2020 05:16 PM

Visit link:
Sharjapan: bringing new technologies and Japanese practices to the Sharjah art scene - The National

JOCELYN MURPHY

jmurphy@nwadg.com

It was a big year for Crystal Bridges Museum of American Art. For a museum thats only 8 years old, every year might conceivably be a big year. But in spite of its youth, the Bentonville museum has already established itself as a trailblazer and continues to achieve impressive new heights with each passing trip around the sun.

In 2019, Northwest Arkansas behemoth arts presenter organized, mounted and traveled a momentous exhibition (Men of Steel, Women of Wonder); activated outdoor spaces in new ways with an internally curated sculpture exhibition and an innovative light and sound installation; explored its namesake in a first-of-its-kind exhibition (Crystals in Art: Ancient to Today); acquired dynamic new works; and is on track to have a record-breaking attendance year.

Its a lot happening, Executive Director & Chief Diversity and Inclusion Officer Rod Bigelow says with a chuckle and a touch of astonishment.

When we landed on the scene, we were labeled a disrupter, he goes on, noting the label was bestowed with both positive and negative implications. I think thats part of our DNA and our culture is that we want to continue to disrupt these discussions and have a bit of a different perspective in the field.

Early on in our life, there was a lot of criticism about who would come to see art in Arkansas, and a lot of discrediting the quality of the experience or where it was. Its good to look back on that now, he muses.

Access

This year, Crystal Bridges honed in on two points of its mission: welcoming all, and presenting a more inclusive narrative of the American experience.

Bilingual presentations in exhibitions were expanded and will continue to increase moving forward. More multi-sensory experiences for visitors with blindness or low vision were widened through a touchable art program. A new cart guide program offers guests a more hands-on way to interact with the work than the traditional walk-through museum experience. And this summer, during the museums outdoor sculpture exhibition focusing on color, Crystal Bridges was gifted 60 pairs of special color-enhancing glasses that were made available for checkout to guests who are colorblind.

The museums commitment to meeting visitors where theyre at so that everyone can experience the art in their own way has translated to almost 5 million visitors since its opening. Before the holidays, Crystal Bridges had already seen an estimated 662,000 visitors this year, surpassing the previous annual attendance record by nearly 30,000.

Outdoors

Outside the museums walls, the grounds at Crystal Bridges were host to myriad experiences the museum had never engaged in before.

We did some creative things this year, including the first campout in the forest, which was fun and exciting, especially for people who dont ever camp, Bigelow shares. And then we did a big Chalk Festival where we had 23 artists come and create a multi-day experience in our parking garage. If you havent seen chalk art being created moment-by-moment, its a fascinating experience. And although it was hot, it was terrific.

The North Forest was also host to two other exciting moments for Crystal Bridges. This summers Color Field was the museums first internally curated outdoor sculpture exhibition and was displayed in conversation with the temporary exhibition at the time, Natures Nation.

In the fall, Crystal Bridges new partnership with Montreal-based multimedia and entertainment studio Moment Factory resulted in the immersive, experiential installation North Forest Lights.

That is a very different kind of experience for us, and that was our intention, Bigelow says of the group of five artistic light and sound installations that are open at night through Feb. 16. What I love about being out in the forest is that every experience is different. And I think thats a poignant impact that weve created in that space and that will continue.

Acquisitions

One of the things that was really important for us this year was our continued growth in our collection, and acquiring objects that are more representative of America, reflects Bigelow.

In focusing on creating a more inclusive view of the American experience, Bigelow reveals curators were very intentional about acquiring works by women artists and artists of color. Two of the new works that have incited significant enthusiasm from viewers are Yayoi Kusamas Infinity Mirrored Room and Kehinde Wileys Portrait of Florentine Nobleman, both on display in the Contemporary Art Gallery.

These and other acquisitions for the Contemporary Gallery instigated the opportunity to re-imagine a portion of the space. Prior to the redesign, the gallerys flow was more chronological. Now, the experience in the immersive Infinity Room abstraction, repetition informs what guests will see in the rest of the gallery space. The section following Kusamas piece is full of newly acquired works by artists concentrating on figuration influenced by abstraction, assistant curator Alejo Benedetti revealed to Whats Up! earlier this year.

Among these contemporary artists of color and female artists pushing boundaries of representation are:

Jordan Casteel, Ourlando; Loie Hollowell, Mothers Milk (featured in 2018 exhibition The Beyond: Georgia OKeeffe and Contemporary Art); Nathaniel Mary Quinn, Dave Forsythe; Emma Amos, The Reader (featured in 2018s Soul of a Nation: Art in the Age of Black Power).

Crystal Bridges also acquired 23 works by Los Angeles-based collector Gordon Bailey this year.

Added to the Early American Art Gallery, pioneering African American artist Henry Ossawa Tanners The Good Shepherd is another important 2019 addition.

Read this article:
Crystal Bridges ups the wow factor in 2019 - The Free Weekly

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced additional patient data from its ongoing Phase I/IIa clinical study of OpRegen, the Companys retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD), a leading cause of adult blindness in the developed world with no FDA-approved treatment options.

The first Cohort 4 patient treated using both a new subretinal delivery system and the Companys new thaw-and-inject (TAI) formulation of OpRegen has continued to demonstrate notable improvements in vision, having gained 25 readable letters (or 5 lines) 6 months following administration of OpRegen RPE cells, as assessed by the Early Treatment Diabetic Retinopathy Scale (ETDRS). This represents an improvement in visual acuity from a baseline of 20/250 to 20/100 in the treated eye. A second Cohort 4 patient has been similarly dosed, and though early, the patient has shown a small improvement in visual acuity in the treated eye at just 14 days following treatment. To date, improvements have become most evident approximately three to six months after treatment. Both patients had rapid healing at the surgical site with no unexpected complications or any serious adverse events.

We are increasingly optimistic about the data we are collecting in dry AMD, stated Brian M. Culley, CEO of Lineage. We have treated five patients in Cohort 4, those with less advanced disease, which more closely match our intended patient population. At the longest-available assessment point for each patient, all five have shown an increase in the number of letters they can read on an ETDRS eye chart. Importantly, these gains have been maintained for as long as 15 months, which is the longest time point for which we have collected data in the better vision cohort. Notably, the first two patients dosed with the new sub-retinal delivery system by Gyroscope Therapeutics and our innovative TAI formulation of OpRegen had no unexpected complications, so we intend to request the removal of the enrollment treatment stagger from the protocol, which should permit us to significantly accelerate our rate of enrollment. Our objective is to combine the best cells, the best production process and the best delivery system, which we believe will position us as the front-runner in the race to address the unmet opportunity in the potential billion-dollar dry AMD market.

We expect 2020 will be a year of major milestones for Lineage. Based on our existing cash and the current value of our marketable securities, we believe we will be able to achieve these milestones under our reduced 2020 spending plan, continued Mr. Culley.

Having dosed a patient with the combination of Gyroscopes recently 510(k)-cleared Orbit Subretinal Delivery System alongside Lineages new thaw-and-inject formulation of OpRegen RPE cells, I found the procedure to be relatively straightforward, leading to the successful delivery of RPE cells to the subretinal space, stated Judy Ju-Yi Chen, M.D., a retinal surgeon at West Coast Retina, San Francisco, CA. I am hopeful that additional procedures will show that this combination provides superior dose control, safety, and efficacy compared to conventional procedures.

The ETDRS eye chart consists of a set of letters of diminishing size on each line. The more letters a patient can read, the better their vision. The Company also is collecting data on rate of geographic atrophy (GA) growth, best corrected visual acuity (BCVA), low-light visual acuity, reading speed, quality of life questionnaires, microperimetry, and assessing structural changes using optical coherence tomography (OCT), fundus autofluorescence (FAF), and color fundus photography.

About the Phase I/IIa Clinical Study

This is a Phase I/IIa open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with geographic atrophy. The study will enroll approximately 24 patients, divided into 4 cohorts. The first 3 cohorts consisted solely of legally blind patients, with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort will include approximately 12 patients with vision ranging from 20/250 to as high as 20/64. Cohort 4 also includes patients treated with one of two formulations of OpRegen; the first 3 patients were treated with a formulation which required plating and preparation of cells one day prior to use. The remaining patients on Cohort 4 will be treated with an off-the-shelf or thaw-and-inject formulation of OpRegen which can be shipped directly to sites and used immediately upon thawing, which removes the complications and logistics of having to use a dose preparation facility. Staggered intervals within and between cohorts are applied to ensure patient safety and welfare. The primary objective of the Phase I/IIa study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additionally, for the patients in Cohort 4 that receive subretinal delivery of OpRegen utilizing Gyroscope Therapeutics Orbit Subretinal Delivery System (Orbit SDS), objectives will include the evaluation of the safety of delivery of OpRegen using the Orbit SDS.

About OpRegen

OpRegen is a retinal pigment epithelium (RPE) transplant therapy in Phase I/IIa development for the treatment of dry AMD, a leading cause of adult blindness in the developed world. OpRegen consists of a suspension of RPE cells delivered subretinally as an intraocular injection. RPE cells are essential components of the back lining of the retina and function to help nourish the retina including photoreceptors. OpRegen has been granted Fast Track designation from the U.S. Food and Drug Administration. OpRegen is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of Lineage Cell Therapeutics, Inc.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the development of Lineages OpRegen program, as well as Lineages spending plans. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Visit link:
Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degeneration -...

IS the Christian faith like the criminal law? Does it compel us to do this or that or face dire consequences? Is it about heavenly rewards for being good and rotten punishments for sin? There is no health in us SPARE Thou those who confess their faults Did Jesus come as another criminal law giver? Or did he come to remove the scales from our eyes to liberate our true nature in the context of one law natural to us, the law of Love? You cant buy that, love, off a shelf. You cant love under orders. No, but we can let it flower within us by giving expression to the governings of our hearts in compassion, in loving kindness. If we and the world suffer, is it really sinfulness for which we call for mercy dont hit us or is it blindness for which we call for liberation, release, from the selves which are not ourselves?

With that in mind, let all our New Years hopes become our dawn. Yes, lets trumpet in a Galilean morn. Its my dawn, and yours. Its a morn which proclaims what Jesus is in our lives, the law of love in action, the love which comes from within us, from the heart where the Kingdom stands, the heart of Jesus within us. He has no need to come again. He never left us.

It was to insinuate all this that last week I wrote of a Eucharist of the imagination, a Mass with no altar, no chalice, paten, host nor wine. Perhaps it sounded very odd. But think about it. Is it really more difficult to turn air into flesh as wine into blood, or water into wine? Theyre all mysteries, arent they? (Is a mystery in this sense a polite word for magic?) We know, well we say and believe, that in the Mass we experience Jesus real presence. Thats a mystery too. We call it a sacrament, an outward and visible sign of an interior, spiritual grace. And when we suppose that thats the product of working with visible, tangible, things, its all very comforting. But do we really have to work with tangible things as the sine qua non for spiritual grace, to experience the real presence?

Remember, Jesus presence is a multiple presence. Hes present, we say, in his Word when the Gospel is read. We say that he presides at the Eucharist in and through his priest. Hes present in the Eucharistic community, those of one body with him. We say we dwell in him and he in us. Hes present whenever two or three are gathered together. In none of these are we talking about a physical presence in a particular place or object. Were talking about a spiritual and personal presence experienced in our hearts and minds, not our stomachs. Its a presence unique to each of us Jesus knows us by our names yet common to all. The bread and wine at the Eucharist give us the focus for that presence, like two shafts of light in a dark room. But theyre not the presence itself.

What does that presence actually mean? It means we acknowledge the divine source of grace within us, Jesus himself. We just know hes there. Its like being in the presence of friends when we read their letters, or by remembering them as when we touch something theyve given us. Its like ever feeling that those weve loved, now dead, are with us, that theyve returned to us as the dead do in time. As with Jesus at the synagogue at Nazareth reading from Isaiah, his presence is as real as if wed said: The Spirit of the Lord is upon me. Its Jesus spirit which rests upon and within us. And what that means is that we too are spiritually anointed, commissioned, to preach the Gospel of Love; and that, love, really doesnt depend on the presence of physical things to give it life. Its as if we have seen with our eyes and touched with our hands the bread of life. And it translates into the Eucharistic prayer: Unite us in Christ and give us your peace that we may do your work and be his body in the world. Yes, we too have been commissioned to do his work, to become his hands, to become the presence of his love. We dont have to manufacture it. Its there within us. Our job is to understand that and live it, and so heal the broken-hearted, preach deliverance to the captives, and recovering of sight to the blind, to set at liberty them that are bruised (Luke 4:18). And this, the presence of Jesus within us to awaken us, the real us, to complete the work he has given us to do, is the most wonderful gift of heaven. The Eucharist, the visible sign of hidden grace, helps us understand that. Tangible things prove nothing. Maybe imagination is even more powerful. So yes, in this New Years dawn what finer commitment to the Jesus within, our hands as his can there possibly be?

Go safely, then until the next time.

New Years resolution, from the boundary: Im not going to die because I failed as someone else. Id rather just succeed at being me (Margaret Cho).

Read more:
FROM THE BOUNDARY: New year, new dawn Part two - Barbados Advocate

By Science News StaffJan. 2, 2020 , 10:50 AM

Incessant political turmoil in the United Kingdom, United States, and other nations will likely last well into the new year, complicating many researchers work. The U.K. election last month made the countrys departure from the European Union a near-certainty, and its scientists now face losing EU science grants and scientific collaborators. In the United States, a presidential election in November will determine the role of scientists in future policy deliberations; many experts on climate change and other environmental issues assert that the Trump administration has ignored scientific evidence. In this section,Sciences news staff forecasts other areas of policy and research likely to make news this year amid the chaos, from dark matter detectors to new efforts to rein in loss of species.

This year will see an attempt to revitalize the ambitious Aichi Biodiversity Targets, named for the city in Japan where they were negotiated. Since they were approved 10 years ago, there has been little to no progress in meeting most of those 20 goals, such as preventing the decline of endangered species. That alarming situation was highlighted last year in a major scientific assessment by another organization, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services. But in October, nations will have a chance to try to set a more effective course when they meet in Kunming, China, to review and revise the Convention on Biological Diversity, the world's flagship conservation pact.

The politics of climate change faces crucial moments this year. The Trump administration's opposition to regulations reducing fossil fuel emissions has emerged as a primary talking point for the president's Democratic challengers. One day after the U.S. presidential election on 3 November, the country, the second largest emitter of greenhouse gases, is set to leave the Paris climate accord, although a Democratic president could quickly rejoin after taking office in 2021. Less than 1 week later, the United Nations will convene in Glasgow, U.K., for its most important climate summit since 2015, where nations are expected to increase their pledges to cut greenhouse gas emissionseven though they are behind on meeting existing ones. Without stepped-up efforts, there is little hope the world can keep future warming below 2C, the level scientists forecast will produce catastrophic damage to human communities and ecosystems.

The U.S. government has conducted a decennial census since 1790. But the 2020 census that kicks off on 1 April faces unprecedented political challenges. Although civil rights groups won a fight to block a question about citizenship that the Trump administration wanted to add, it has ordered the Census Bureau to generate the equivalent data using existing government records so that states can use the information when they redraw boundaries for federal and state elections. Researchers fear that assignment may not be doable, and that the political debate has further alienated those already hardest to count. Demographers also worry that the census' use of a new way to protect respondents' privacy could distort analyses of demographic trends. At stake are not only how more than $1.5 trillion in federal funds are distributed each year, but also the integrity of the nation's largest statistical agency.

The CRISPR gene-editing tool faces key tests this year of its promise to treat cancer and genetic diseases. A small U.S. clinical trial is using CRISPR to disable three genes in T cells that are then returned to a cancer patient's body, an approach that could help these immune system soldiers stop malignant cells from growing and extend patients' lives. More results may also come from separate CRISPR cancer trials in China. Other researchers are working to treat people with sickle cell disorder and thalassemia by using the DNA editor to turn on the gene for a fetal version of hemoglobin to compensate for a defective adult form of the oxygen-carrying protein; last fall, scientists reported success in two patients and in 2020 will present longer-term results for a larger group. Another clinical trial in the United States could show whether CRISPR improves vision in people with an inherited disorder that causes progressive blindness.

Ancient proteins will shed new light this year on the identity and behavior of humans and other animals that lived more than 1 million years ago. Proteins are more stable than DNA, and as analytical methods improve, researchers can apply them to understand more about older fossils lacking DNA, including the sex and age of remains of enigmatic ancient hominins. Most hominins are known by bones and teeth alone, and proteins could provide a new tool for sorting them in family trees and to identify fragments too small to classify. Although tooth enamel offers the best source of ancient proteins, researchers are also extracting them from bones and hair. In addition, proteins can reveal new information about artifacts made of plant and animal materials, and researchers hope this year to analyze parchment manuscripts and the beeswax once used to seal documents. Scientists are also analyzing residues on pots for more clues to whether early pastoralists in the steppelands of Mongolia, for example, drank camel or goat milk firstand what people living on the edge of the Roman Empire in England ate.

Proteins in these 400-year-old bone fragments, found in Iroquois settlements in Canada, revealed whether they were animal or human.

The political debate over how to respond to China's emergence as a scientific superpower is likely to intensify this year. In the United States, some federal agencies have banned their employees from participating in foreign talent recruitment programsan approach that China has used to connect with thousands of scientiststo prevent disclosure of information that could damage national security and U.S. economic competitiveness. Two new bodies created by Congress will work to harmonize practices across federal agencies and chew over how best to balance openness and security. U.S. academic leaders are hoping to convince policymakers not to fence off certain types of research, which they say would throttle U.S. innovation. A new report to the National Science Foundation says teaching students and faculty members about acceptable and unacceptable behavior is a better approach.

Japan is expanding neutrino research to better understand properties of the phantom particles and the cosmic processes that produce them. This spring, scientists will increase the sensitivity of the 22-year-old Super-Kamiokande neutrino observatory by doping water in its observation chamber with the rare-earth metal gadolinium. The detector will then watch for signals generated when neutrinos from supernovae hit the water, providing clues about the dynamics within those exploding stars. Japan's legislature is expected to fund an even bigger step: construction of the 72 billion Japanese yen ($660 million) Hyper-Kamiokande. Ten times larger than its predecessor, it will capture that much more data about neutrinos emanating from the Sun, distant stars, and supernovae.

The race to detect hypothetical particles of dark matterthe invisible stuff that binds together the galaxies with its gravityenters a new phase this year with the startup of two powerful new underground detectors. Since the 1980s, physicists have used ever bigger and more sensitive ones to search for so-called weakly interacting massive particles (WIMPs), theorized to weigh 100 times as much as protons and to interact with other matter only through the feeble weak nuclear force. This year, the XENON-NT detector, which contains 8 tons of frigid liquid xenon, will turn on in the subterranean Gran Sasso National Laboratory in Italy. At the Sanford Underground Research Facility in South Dakota, the LUX-ZEPLIN (LZ) detector, which contains 10 tons of liquid xenon, will also power up. If XENON-NT and the LZ see nothing in the next few years, dark matter hunters could push for bigger WIMP detectors or set their sights on other hypothesized forms of dark matter. The Italian lab's future also remains uncertain, as former lab officials face prosecution for allegedly allowing contamination of local drinking water.

The LUX-ZEPLIN dark matter detector is readied to record data at an underground lab in South Dakota.

The genome editor CRISPR is reinvigorating the beleaguered field of xenotransplantation, which aims to surgically replace human organs or tissues with ones harvested from animals such as pigs. Novel clinical trials of the strategy could launch this year. Xenotransplantation has long promised to alleviate a chronic shortage of human livers, hearts, and other organs. It could also provide corneas to cure blindness and insulin-producing islet cells to replace those destroyed by diabetes. But time and time again in earlier tests, human immune systems have quickly destroyed the foreign transplants. Recent CRISPR experiments have modified genes in pigs to prevent or dampen human immune responses to their tissue and have removed DNA from the porcine genome that could spawn potentially dangerous viruses in a person. Transplants from these edited pigs to monkeys, a key test of safety and efficacy before human trials, have demonstrated long-term viability in their new hosts.

This year, China is expected to win the race to build the world's first exascale computer, capable of carrying out 1 billion billion (1018) calculations per second, also known as an exaflop. Just which supercomputer will be the first remains uncertain, as China has set up a competition between three institutions: the National Supercomputing Center of Tianjin, the National Supercomputing Center in Jinan, and Dawning Information Industry Co., a manufacturer also known as Sugon. The new Chinese supercomputers, and others to follow in the European Union, Japan, and the United States, will be used to analyze vast data sets from astronomical and genetic surveys, and will support the continued rise of artificial intelligence. Some computer scientists expected the exascale milestone to have come sooner; delays resulted in part from the need to develop energy efficient computer chips.

Alzheimers drug The U.S. Food and Drug Administration will decide whether to approve aducanumab, an antibody drug designed to bust the brain-clogging amyloid plaques of Alzheimer's disease. The experimental treatment has shown mixed success in clinical trials.

Ocean conservation The United Nations intends to finish plans for a Decade of Ocean Science to begin in 2021. The goal is to coordinate work by scientists around the world to help improve ocean health. One expected emphasis is mapping more of the world's vulnerable marine ecosystems and biodiversity hot spots and more of the ocean's bottom, only about 4% of which has been charted in high resolution.

Stem cell funding California voters will decide in November whether to allocate $5.5 billion from bond sales to keep alive the California Institute for Regenerative Medicine. The funding agency was created through a $3 billion ballot initiative in 2004 to translate stem cell research into new therapies.

Curated and edited by Jeffrey Brainard.

Here is the original post:
The science stories likely to make headlines in 2020 - Science Magazine

Diabetic retinopathy (DR) is a sight-threatening complication of diabetes and the main cause of blindness in the United States among working adults. Initially, DR progresses as a non-proliferative DR (NPDR) which leads to blinding proliferative DR (PDR). Nearly all people with Type 1 Diabetes (T1D) undergo gradual vision loss over a 20-year period of diabetes, and about 2030% of them progress to the advanced blinding stage of the disease, PDR.

Tight glycaemic management lowers the risk of complications, yet, many diabetic patients develop DR, despite having good glycaemic control. Furthermore, there is no cure or a preventive measure to block PDR. Only recently, over the past decade, with the advent of medicines that block the actions of the vascular endothelial growth factor (VEGF), has considerable progress been made in therapeutic options for PDR.

Nevertheless, not all patients achieve a satisfactory response and many of responders experience frequent invasive intravitreal injections and off-target effects, including increased risk of neuronal toxicity and geographic atrophy. While additional molecular targets, including the plasma kallikrein pathway, lipoprotein-associated phospholipase A2 (Lp-PLA2) and Tie-2, have been identified, with some being clinically evaluated, a critical gap still remains ineffective treatments.

Evidence suggests that targeting DR in the earlier stages, such as mild to moderate NPDR, before permanent damage occurs, would provide long-term benefit. In recent years, our research has focused on the molecular mechanisms of early DR including retinal oxidative stress, mitochondrial dysfunction, mitophagy, inflammation, and premature cell death in diabetes using both in vitro retinal cell cultures and in vivo diabetic rodent models.

Intriguingly, we have discovered a protein called thioredoxin-interacting protein (TXNIP) is strongly induced by diabetes in early DR where it is responsible for mediating cellular oxidative stress, mitophagy, inflammation and premature cell death. Knockdown of TXNIP by intravitreal injection of TXNIP shRNA prevents early molecular defects seen in DR. TXNIP binds to and inhibits the anti-oxidant and thiol-reducing capacity of thioredoxins (Trx) causing cellular redox imbalance and oxidative stress. Trx1 is present in the cytosol and nucleus while Trx2 is located in the mitochondrion. TXNIP is observed in all cellular compartments. Therefore, targeting TXNIP itself or downstream pathways could prevent or slow down the progression of early DR (NPDR) and hence PDR.

Currently, no clinically used, professional TXNIP inhibitors exist; however, several FDA-approved medicines have been reported to interfere with TXNIP pathway, but none of them has been used to treat DR. These drugs include amlexanox, tranilast, and romidepsin and they have been extensively studied for their efficacy, toxicity and safety. This consequently leads to saving time and money and may accelerate their entry to experimental clinical trials centred on targeting an over-activated TXNIP system to arrest DR away from their initial use.

Amlexanox is an inhibitor of TANK-Binding Kinase 1 (TBK1), which phosphorylates mitophagy adaptor optineurin and regulates mitophagic flux to lysosomes. In addition, TBK1 also phosphorylates interferon responsive factor 3 (IRF3) and mediates Type 1 interferon expression and inflammation. Tranilast has been shown to inhibit TXNIP and Nod-like NLRP3 inflammasome; therefore, it may help in preventing cellular oxidative stress and innate immune responses.

Therefore, a combination therapy using amlexanox and tranilast may prove to be effective in preventing or slowing down the progression of DR. Recently, we also demonstrated that a combination therapy of SS-31 (a mitochondria-targeted anti-oxidant), amlexanox and tranilast prevents auranofin-induced redox stress, mitochondrial-lysosomal axis dysregulation and proinflammatory pyroptotic cell death in retinal pigment epithelial cells, suggesting that combination therapies may be more effective than a single drug therapy.

In addition to drug treatment, gene therapy using a TXNIP promoter linked with a neuroprotective factor or an anti-oxidant gene may also be a potential approach for DR treatment. This is because the TXNIP promoter is strongly induced by hyperglycaemia in retinal cells in culture and in diabetic rodent retinas, but not under physiological glucose levels. In addition, the TXNIP promoter is also activated significantly by histone deacetylase inhibitors (HDACi), including suberoylanilide hydroxamic acid (SAHA) or romidepsin.

Therefore, HDACi and TXNIP-promoter gene therapy may also be incorporated in DR therapy for retinal neuroprotective gene expression, which could include pigment epithelium-derived factor (PEDF), glia-derived neurotrophic factor (GDNF), thioredoxin encoded Rod-Derived Cone Viability Factor (RdCVF) and others. These factors are known to be downregulated in DR.

It is currently accepted that neurodegeneration (particularly photoreceptor dysfunction) occurs early in DR before microvascular pathology develops. Therefore, early neuroprotective efforts may constitute a meaningful therapeutical approach to prevent or slow down the progression of late microvascular complications and PDR. Diabetes is a chronic and complex metabolic disease in which PDR develops only after prolonged hyperglycaemic exposure.

Therefore, a window of diabetic duration may exist early to prevent retinal neurovascular dysfunction and progression of PDR; within this time frame, we may devise preventive interventions activating endogenous genes or factors with neuroprotective drugs (preferably orally active drugs) and gene therapy including those mentioned above.

Such a hypothesis is supported by a recent observation, which showed that the expression of retinol binding protein 3 (RBP3), a protein secreted by photoreceptors in the retina, may play a protective role against PDR. RBP3 interacts with glucose transporter Glut1 and reduces excess cellular glucose uptake under hyperglycaemia in diabetics, thus, preventing glucotoxicity in retinal cells including Muller glia and capillary endothelial cells. Those individuals expressing RBP3 do not develop PDR although they have had 50 years of T1D.

In conclusion, new preventive therapies for PDR may be successfully developed by activating endogenous cellular survival mechanisms using drug and gene therapies once a clinical sign of NPDR is observed but before PDR. Such treatments may prevent blindness in diabetic patients.

References

1 Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010 Aug 19;1:e65. PMID: 21364670.

2 Devi TS, Somayajulu M, Kowluru RA, Singh LP. TXNIP regulates mitophagy in retinal Mller cells under high-glucose conditions: implications for diabetic retinopathy. Cell Death Dis. 2017 May 11;8(5):e2777. PMID: 28492550.

3 Lalit PS, Thangal Y, Fayi Y, Takhellambam SD. Potentials of Gene Therapy for Diabetic Retinopathy: The Use of Nucleic Acid Constructs Containing a TXNIP Promoter. Open Access J Ophthalmol. 2018;3(2). PMID: 31106306.

4 Devi TS, Yumnamcha T, Yao F, Somayajulu M, Kowluru RA, Singh LP. TXNIP mediates high glucose-induced mitophagic flux and lysosome enlargement in human retinal pigment epithelial cells. Biol Open. 2019 Apr 25;8(4). PMID: 31023645.

5 Yumnamcha T, Devi TS, Singh LP. Auranofin Mediates Mitochondrial Dysregulation and Inflammatory Cell Death in Human Retinal Pigment Epithelial Cells: Implications of Retinal Neurodegenerative Diseases. Front Neurosci. 2019 Oct 10;13:1065. PMID: 31649499.

6 Yokomizo H, Maeda Y, Park K, Clermont AC, Hernandez SL, et. al., Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med. 2019 Jul 3;11(499). PMID: 31270273.

7 Ibrahim AS, Saleh H, El-Shafey M, Hussein KA, et. al., Targeting of 12/15-Lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis. BBA: Mol Cell Biol Lipids. 2017 Jun;1862(6):636-645. PMID: 28351645.

8 Ibrahim AS, Elshafey S, Sellak H, Hussein KA, El-Sherbiny M, et. al., A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res. 2015 Mar;56(3):599-611. PMID: 25598081.

Funding

NIH/NEI R01 EY023992 (LSP, OVAS).

NIH/NEI core grant P30EY004068 (LDH, OVAS).

Research to Prevent Blindness (MSJ, OVAS).

American Heart Association Grant 18CDA34080403 to ASI.

Please note: This is a commercial profile

Editor's Recommended Articles

Continued here:
Repurposing FDA-approved medicines and gene therapy to combat diabetic retinopathy - Open Access Government

Global Musculoskeletal Disorder Stem Cell Therapy Market Growth (Status and Outlook) 2019-2024 Overview :

According to this study, over the next five years the Musculoskeletal Disorder Stem Cell Therapy market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024

A newly revealed market research study titledGlobal Musculoskeletal Disorder Stem Cell Therapy MarketbyMRInsights.biz, studies market insights, list of significant key professionals, threats of new competitors and alternate products. The report presents in-depth analysis along with competitive insights, segmentation, and the market size information. In addition, it exploresMusculoskeletal Disorder Stem Cell Therapymarket size, trends, share, growth, development plans, growth opportunity, cost structure and drivers analysis.One part of this report contains production in which analysis on the production, revenue, gross margin of its main manufacturers in different regions from 2014 to 2019 has been covered. It also makes a prediction of its production and consumption in coming 2019-2024. The report provides a detailed analysis by the categorization of the global market on the basis of regions.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/177475/request-sample

Globally top leading manufacturers listed here: Osiris Therapeutics, NuVasive, Takeda (TiGenix), Medi-post,

Market region segmentation:

Furthermore, the SWOT analysis and strategies of each vendor are highlighted in the report which can be employed to create future opportunities.It sheds light on its applications, types, deployments, components, growths of this market. The research has also carried out analysis on upstream raw materials, equipment and downstream consumers. Next, it analyzes volume, utilization value, sale price, import and export in different regions from 2014 to 2019. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, while for end use/application segment, this report focuses on the status and outlook for key applications.

The GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Report Contains:

Next, the raw data collected through several sources has been processed using various mathematical and analytical tools and techniques in order to conclude the significant information related to future growth prediction trend for 2019 to 2024 time frame. At the end, research findings and conclusions specified in the report will help decision makers to take vital choices in the near future.

READ FULL REPORT:https://www.mrinsights.biz/report/global-musculoskeletal-disorder-stem-cell-therapy-market-growth-177475.html

There are 12 Chapters to deeply display the globalMusculoskeletal Disorder Stem Cell Therapymarket.

Chapter 1:Scope of the Report

Chapter 2:Executive Summary

Chapter 3:GlobalMusculoskeletal Disorder Stem Cell Therapyby Manufacturers

Chapter 4:Musculoskeletal Disorder Stem Cell Therapyby Regions

Chapter 5, 6, 7, 8 and 9:Americas,APAC,Europe,Middle East & Africa,Market Drivers, Challenges and Trends

Chapter 10 and 11:GlobalMusculoskeletal Disorder Stem Cell TherapyMarket Forecast,Key Players Analysis

Chapter 12 :Research Findings and Conclusion.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read this article:
Global Musculoskeletal Disorder Stem Cell Therapy Market 2019 2024 Qualitative and Quantitative Assessment by Industry Analysis across the Value...

ORLANDO, Fla.--(BUSINESS WIRE)--Amnion of Florida, a leading provider of alternative medicine utilizing cryopreserved placental cell allograft for advanced bioactive facial rejuvenation, is pleased to announce a partnership to enhance patient outcomes for joint pain and anti-aging therapies.

Amnion announces a partnership with Care First Medical Group, Inc. to improve patients experience with managed medical care and provide non-pharmaceutical solutions for joint repair/pain management and anti-aging. The goals of the collaboration are to provide alternatives to medical care and to help patients seeking to eliminate chronic joint pain, look younger, and take a more active role in mapping their medical care to avoid illness in the future.

Sabriya Rogers, President of Care First, states, Our Board-Certified primary care providers specialize in managed health, thus patients can take a proactive approach in deciding the course of their care, which yields a lower cost to patients, while keeping families together, and maintaining a high degree of medical care.

The partnership will provide more location options for patients. With offices throughout greater Orlando, Sanford, Leesburg, Palm Coast, and Longwood, patients will find a location nearby that fits busy schedules.

Our team of medical professionals and aestheticians at Amnion are excited to partner with Care First to provide enhanced medical care and rejuvenation services at our partnership locations, said Eusebio Coterillo, President of Amnion.

In a constantly changing field, Amnion of Florida, under the guidance of an on-site medical staff, provides the highest level of quality products and procedures in regenerative medicine. They offer cutting edge treatments that are shown to be effective, use FDA cleared or registered products, and are widely published and peer endorsed. The collaboration with Care First will bring added benefits such as managed care, urgent care, and programmed care for long term issues such as high blood pressure, diabetes, high cholesterol, asthma, and allergies in a full-service clinical setting.

More about Amnion of Florida

Amnion of Florida, based in Central Florida, is a leading provider of alternative medicine using cryopreserved placental cell transplants or allografts, processed from donated cellular birth tissue, which are natural alternatives to autologous regenerative medicine products. The primary function of our allogeneic regenerative treatments is to promote soft tissue joint/skin repair and regeneration mediated by growth factors and cells naturally found in placental tissue. These treatments have shown safety and efficacy in treating a variety of ailments including osteoarthritis, chronic ulcerative wounds, joint pain, skin rejuvenation, hair restoration, urinary incontinence, and ED. Learn more at http://www.amnion.us.

More about Care First Medical Group, Inc.

Care First, based in Central Florida, is focused on providing affordable healthcare for primary and urgent care needs through prevention, patient education, with the personal touch to improve communication with the patient, and patients overall health. Our vision is to transform the health care experience through a culture of caring, quality, safety, service, innovation, and excellence. Our goal is to be recognized by employees, physicians, patients and families, volunteers, and the community as a company that delivers results through our proactive approach to medicine. Learn more or schedule an appointment at (407) 449-0632.

Read this article:
Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group - Business...

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is theBuzz of BIO 2020 winnerin the Public Therapeutic Biotech category.

The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is anopportunity to make investor connections that could take products to the next phase.

Ten biotechnology companies are nominated in each of the three categories ofBuzz of BIO: Public Therapeutic Biotech, Private Therapeutic Biotech, and Diagnostics and Beyond. In the Public Therapeutic Biotech category that BrainStorm won, nominated companies must be actively developing a publicly traded human treatment intended for review by theU.S. Food and Drug Administration (FDA).

As a developer of autologous cellular therapies treatments that use a patients own cells and tissues for debilitating neurodegenerative diseases, BrainStorm is now testing its NurOwn therapy for safety and effectiveness. The treatment involves extracting, from human bone, marrow-derived mesenchymal stem cells (MSCs), which are capable of differentiating into other cell types. The MSCs are then matured into a specific cell type that produces neurotrophic factors compounds that promote nervous tissue growth and survival. They are then reintroduced to the body via injection into muscles and/or the spinal canal.

Backed by a California Institute for Regenerative Medicine grant, Brainstorm has fully enrolledits randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03280056) at six U.S. sites in California, Massachusetts, and Minnesota. Some 200 ALS patients are participating. A secondary safety analysis by the trials independent Data Safety Monitoring Board (DSMB) revealed no new concerns. Every two months, study subjects will be given three injections into the spinal canal of either NurOwn or placebo.

The trial is expected to conclude late this year. Results will be announced shortly afterward.

In a Phase 2 study (NCT02017912), which included individuals with rapidly progressing ALS, NurOwn demonstrated a positive safety profile as well as prospective efficacy.

The use of autologous MSC cells to potentially treat ALS was given orphan drug status by both the FDA and the European Medicines Agency.

Thanks to everyone who voted for BrainStorm during the Buzz of BIO competition,Chaim Lebovits, BrainStorm president and CEO, said in a press release. The entire management team at BrainStorm was very pleased with the results of this competition, and we look forward to presenting to an audience of accredited investors who may benefit from the companys story. We thank the BIO[Biotechnology Innovation Organization] team for singling out BrainStorms NurOwn as a key technology with the potential to improve lives.

As a contest winner, BrainStorm is invited to givea presentation at theBio CEO & Investor Conference, to be held Feb. 1011 in New York City, along with exposure to multiple industry elites and potential investors.

NurOwn cells also are being tested in a Phase 2 clinical study (NCT03799718) in patients with progressive multiple sclerosis.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Link:
BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today

XconomyNational

Cell and gene therapies are becoming more mainstream, but an essential aspect of the drug development process is talking with clinicians about how it would fit into their practice, according to Joe Dupere, CEO of UK-based regenerative medicine company Rexgenero.

Rexgenero is advancing an experimental cell therapy for critical limb ischemia, a chronic condition that causes severe burning pain in the feet or toes as a result of blocked arteries in the lower limbs. Patients often get ulcers that can lead to amputation of the affected limb.

The company, headquartered in London, has R&D and manufacturing operations in Spain. Dupere talked with journalist Mike Ward at BIO-Europe 2019 in Hamburg, Germany, about the companys progress and plans.

Theres a lot of dialogue with the physicians and the surgeons that we cooperate with in our trial so they understand our product, its place in the treatment of this disease, and understanding when they can bring in patients and potential benefits, Dupere said.

When it comes to involving clinicians in its studies, the earlier, the better, Dupere said he learned as the company advanced its investigational treatments.

We live and breathe our design of our study, but surgeons are coming into this new, and to really understand how it works and really assist them in that journey with us so that they can bring patients in, we make it as easy as possible for them to participate, he said.

Although the type of treatment isnt as unusual as it once was, detailing how Rexgeneros cell therapies could impact how care is currently provided is essential to getting buy-in from the physicians who would use it, he said.

The challenge for us is to really demonstrate the superiority, in terms of the efficacy that we can show, and how that fits in with their practice, he said. Thats also marrying what they do already, which is a series of surgical and in endovascular procedures, [with] where the cell therapies can come in and really turbocharge that and have a really substantial impact on their patients.

As Rexgenero focuses on its Phase 3 trials, its priorities have included thinking through how the product would be used if it were to make it to commercialization.

Theres a whole range of other activities that we need to focus on as we get nearer to the market, he said.One is scaling up the manufacture, so thats a truly commercial manufacturing process that can really deliver the product to as many patients as possible. The second is really understanding how this would be used in practice, so from a commercial perspective, how would you sell this product, how would you position it with the physicians, and how would you get the surgeons to understand where this treatment would work in their general practice.

Duprere said the company also aims to expand into supplementary indications and establish a presence in the US.

Talking with investors as BIO-Europe, Duprere said he noticed more of an appreciation for biotechs that are doing cell therapy work outside of immune-oncology, a hot area for life sciences financings.

I think when you talk about [strategic investors], the core value proposition of the disease and the treatment of the disease and the unmet need of the disease has been understood from the beginning, but utilization of a cell therapy to be able to address that market is something that theyre getting much more familiar with, certainly around things like the manufacture, some of the regulation thats specific to cell therapies, and also the commercial path, when youre dealing with a curative product where you give a single dose of the product and you expect a cure for the patient.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

View original post here:
Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations - Xconomy

MEDIA CONTACT

Available for logged-in reporters only

9th Annual Glaucoma 360, February 6 to 8, 2020, San Francisco

Newswise San Francisco, CA January 2, 2020: Glaucoma Research Foundation (GRF) will host the 9th Annual Glaucoma 360 from February 6 to 8, 2020 in San Francisco. This signature three-day event highlights innovation in glaucoma therapies to ensure patients have access to the latest and most effective diagnostic tools and treatment options. All Glaucoma 360 events will take place at the Grand Hyatt San Francisco in Union Square.

Glaucoma 360 begins on Thursday evening (February 6th) with a fundraising Gala. At the Gala, the 2020 Catalyst Award will be presented toVicente Anido, Jr, PhD and Thomas A. Mitro from Aerie Pharmaceuticals, Inc., in recognition of their remarkable leadership and commitment to the development of innovative glaucoma treatments.

During the Gala, Glaucoma Research Foundation will also be recognizing extraordinary research with the following presentations:

The New Horizons Forum on February 7th will feature more than 60 speakers from companies developing innovative glaucoma therapies and diagnostics. This full-day meeting co-founded and co-chaired byAdrienne L. Graves, PhDandAndrew G. Iwach, MD, spotlights new and promising developments to diagnose and treat glaucoma, a leading cause of preventable blindness worldwide. Since its inception in 2012, this meeting has grown substantially, attracting key clinical, scientific, industry, financial, and regulatory leaders from across the United States and around the world.

We will once again feature early-stage companies and their new technologies and approaches to glaucoma care, said Dr. Graves. The amount of innovation that is flourishing in the glaucoma space right now is phenomenal. As a result, there are more therapeutic options than ever before to help patients. Glaucoma 360 is an important catalyst to bring all the important elements together that can advance a promising idea into clinical use, she said.

Dr. Iwach added, For our 2020 New Horizons Forum, in addition to highlighting new developments in glaucoma diagnostics and therapies, there will also be a session on Innovation 101 that will discuss how you move from a great idea into the next breakthrough therapy for patients. The FDA will be involved in this session as their guidance is critical to get new and more effective solutions to our patients.

David W. Parke II, MD, Chief Executive Officer of the American Academy of Ophthalmology (AAO), will deliver the Drs. Henry and Frederick Sutro Memorial Lecture, the Forums keynote address. Dr. Parkes lecture, When Cost and Innovation Collide in Ophthalmology, will highlight the Academys role in facilitating innovation through collaboration with industry partners, AAO members, and AAO resources such as the IRIS registry the nation's first comprehensive eye disease clinical registry.

Glaucoma 360 will conclude on Saturday, February 8th with continuing medical education symposia for ophthalmologists and optometrists. The Shaffer-Hetherington-Hoskins Keynote Lecture on Saturday morning will be presented byDale K. Heuer, MD, Retired Professor and Chair of Ophthalmology and Visual Sciences, Medical College of Wisconsin in Milwaukee. More than 1,000 attendees are expected to participate over the three days of Glaucoma 360. All proceeds from the events support Glaucoma Research Foundations research and educational programs. To learn more about Glaucoma 360 events and to register, visit:www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in San Francisco in 1978, Glaucoma Research Foundation is Americas oldest and most experienced institution dedicated to its mission to cure glaucoma and restore vision through innovative research. The Foundation has a proven track record of pioneering, results-oriented research and produces definitive educational materials used by eye care professionals across the country. The Glaucoma Research Foundation website,www.glaucoma.org, provides valuable information about glaucoma to 4 million visitors annually.

For more information about Glaucoma Research Foundation and Glaucoma 360 events, please contact, Brizette Castellanos at 415.986.3162, ext. 221, or brizette@glaucoma.org or visitwww.glaucoma360.org.

Continue reading here:
Glaucoma Research Foundation to Host 9th Annual Glaucoma 360 at Grand Hyatt in San Francisco - Newswise

At the 200-year mark, some institutions would be content to rest on their laurels. But not Indiana University. As their bicentennial celebrations nears, the Hoosiers have dedicated themselves to a tackling what they are calling Grand Challenges, a suite of economic, social and environmental problems plaguing Indiana and the world. These challenges are marked by their impressive scale, immense impact, driven commitment to solutions, and a spirit of interdisciplinary collaboration.

One of the Grand Challenges is the Precision Health Initiative, which aims to match patients more closely and carefully with treatments that meet their individual needs. According to Anatha Shekhar, the executive associate dean of research affairs at the Indiana University School of Medicine, the initiative derives that precision by taking a decidedly holistic look at a patient's health.

"What we're trying to do here is to have a comprehensive approach to understanding a person's health, taking into account their genetics, their environment, their behavior, their culture, and to understand the diseases that are caused by these factors," Shekar explains. "We're particularly focusing on five major serious illnesses that currently have no good treatments and that are uniformly lethal or disabling."

Those five diseases include three types of cancer: triple-negative breast cancer, multiple myeloma, and pediatric sarcoma. They're also targeting diabetes, in particular gestational diabetes affecting pregnant women, as well as Alzheimer's disease.

The Precision Health Initiative was the first project to receive Grand Challenges funding. A truly transformative undertaking, Indiana is pulling together researchers and physicians from across the university ecosystem to create new approaches to prevention, treatment and health care delivery.

"The Precision Health Initiative is trying to just marshal the great resources we have here, all the scientific minds, all the technology, to attack big, bold problems," says Aaron Carroll, professor of pediatrics and associate dean for research mentoring at the IU School of Medicine.

The project is funneling $120 million into six different major scientific pillars: Genomic Medicine; Cell, Gene & Immune Therapy; Regenerative Medicine & Engineering; Psychosocial, Behavioral & Ethics; Data & Informatics; and Chemical Biology & Biotherapeutics.

Carroll likens it all to a moonshot. Where research is normally understood to move slowly, taking tiny steps towards a solution, Indiana seeks great strides founded in unfettered access to both real and mental capital. And, as the only medical school in the state, as well as a regional and national research leader, their charge is an imperative. "It's certainly very Hoosier. I think the idea that we're going to take our local expertise and really try to band together and cross boundaries to try to make a big difference, it's, it's very Indiana," Carroll says.

Clinically speaking, the Precision Health Initiative is not just seeking to draw down instances of the maladies their targeting. Rather, they seek wholesale cures for the cancers, and robust, workable preventative measures for diabetes and Alzheimer's disease.

Their patient-focused approach is already being taught to physicians-in-training at the IU School of Medicine. The importance of factors such as genetic and family medical history, sleep and eating habits, exercise levels and overall mental health is emphasized alongside traditional testing in making a diagnosis.

In the lab, Indiana researchers are matching that holistic approach to patient health with an equally vibrant understanding of how diseases operate. They're working towards a more-perfect model of exactly how cancers evolve and how they become resistant to certain treatments. Concurrently, pharmaceutical scientists are making gains in drug discovery for the treatment of Alzheimer's.

Shekhar says that the feeling among the Precision Health Initiative team is that the work being done now is serving as inspiration for others to "think big and to go for the fences rather than do incremental work."

There are, though, factors limiting the speed at which the team can make new discoveries. Key among them is the need for an expansion in data analysis and management as well as advances need in AI to help researchers make sense of extremely large data sets.

One such set derives from the All In project, which is under the Precision Health Initiative umbrella. Researchers are asking people from across the state and all walks of life to share with them a blood sample as well as specific, yet anonymous health data. This will aid immensely in their understanding of how and why diseases flourish and progress in various populations.

That particular project is indicative of the larger initiative, says Shekhar, echoing Carroll's sentiment that Indiana is uniquely positioned to helm such an audacious undertaking.

"I think Indiana is unique in that first of all, we have the largest medical school in the country, that is a state wide medical school with nine campuses," he says. "We have the largest health system in the state. We serve about two million people every year for their health needs. So, we have gone all the way from engaging large scientific teams, recruiting nearly 50 new scientists to Indiana University to work on this, to engaging nearly hundred thousand people from the community. It's an initiative that couldn't happen in very many places except in Indiana."

See the rest here:
Inside Indiana's Precision Health Initiative: BTN LiveBIG - Big Ten Network

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

Continue reading here:
Supply Chain Management Software Solutions Market Will Grow Significantly in Coming Years - Supply and Demand Chain Executive

Dublin, Jan. 03, 2020 (GLOBE NEWSWIRE) -- The "Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions" report has been added to ResearchAndMarkets.com's offering.

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030 report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. An Introduction to Cell and Advanced Therapies3.2.1. Classification of Advanced Therapy Medicinal Products3.2.2. Current Market Landscape3.3. Cell and Advanced Therapies Supply Chain3.3.1. Key Processes3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management3.4.1. Cell Orchestration Platform3.4.2. Enterprise Manufacturing System3.4.3. Inventory Management System3.4.4. Laboratory Information Management System3.4.5. Logistics Management System3.4.6. Patient Management System3.4.7. Quality Management System3.4.8. Tracking and Tracing System3.5. Growth Drivers and Roadblocks3.6. Emergence of Digital Technologies in Supply Chain Management3.6.1. Blockchain Technology3.6.2. Internet of Things3.6.3. Augmented Reality3.6.4. Big Data Analytics3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape4.2.1. Analysis by Type of Software Solution4.2.2. Analysis by Key Specification and Benefit4.3.3. Analysis by Application4.3.4. Analysis by End User4.3.5. Analysis by Mode of Deployment4.3.6. Analysis by Scale of Management4.3.7. Analysis by Regulatory Certifications / Accreditations4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape4.2.1. Analysis by Year of Establishment4.2.2. Analysis by Location of Headquarters4.2.3. Analysis by Size of Company4.3.4. Analysis by Support Services Offered4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES6.1. Chapter Overview6.2. Brooks Life Sciences6.2.1. Company Overview6.2.2. Financial Information6.2.3. BiobankPro: Software Description6.2.4. Recent Developments and Future Outlook6.3. Cryoport6.3.1. Company Overview6.3.2. Financial Information6.3.3. Cryoportal: Software Description6.3.4. Recent Developments and Future Outlook6.4. MasterControl6.4.1. Company Overview6.4.2. MasterControl Platform: Software Description6.4.3. Recent Developments and Future Outlook6.5. SAP6.5.1. Company Overview6.5.2. Financial Information6.5.3. SAP S/4HANA: Software Description6.5.4. Recent Development and Future Outlook6.6. Savsu Technologies6.6.1. Company Overview6.6.2. Financial Information6.6.3. evo Cold Chain 2.0: Software Description6.6.4. Recent Development and Future Outlook6.7. TraceLink6.7.1. Company Overview6.7.2. Financial Information6.7.3. Digital Supply Chain Platform: Software Description6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS7.1. Chapter Overview7.2. Supply Chain Orchestration Platforms7.2.1. Key Functions of Supply Chain Orchestration Platforms7.2.2. Advantages of Supply Chain Orchestration Platforms7.2.3. Supply Chain Orchestration Platform Implementation Strategies7.3. Supply Chain Orchestration Platform: Trends on Twitter7.3.1. Scope and Methodology7.3.2. Historical Trends in Volume of Tweets7.3.3. Popular Keywords7.4. Key Industry Players7.4.1. Be The Match BioTherapies7.4.2. Clarkston Consulting7.4.3. Haemonetics7.4.4. Hypertrust Patient Data Care7.4.5. Lykan Bioscience7.4.6. MAK-SYSTEM7.4.7. sedApta Group7.4.8. Stafa Cellular Therapy7.4.9. Title 21 Health Solutions7.4.10. TrakCel7.4.11. Vineti

8. FUNDING AND INVESTMENT ANALYSIS8.1. Chapter Overview8.2. Types of Funding8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances8.3.1. Analysis by Number of Funding Instances8.3.2. Analysis by Amount Invested8.3.3. Analysis by Type of Funding8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions8.3.5. Most Active Players: Analysis by Amount Invested8.3.6. Most Active Investors: Analysis by Participation8.3.7. Geographical Analysis by Amount Invested8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS9.1. Chapter Overview9.2. Partnership Models9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships9.3.1. Analysis by Year of Partnership9.3.2. Analysis by Type of Partnership9.3.3. Analysis by Partner's Focus Area9.3.4. Analysis by Type of Software Solution9.3.5. Most Active Players: Analysis by Number of Partnerships9.3.6. Analysis by Regions

10. PLATFORM UTILIZATION USE CASES10.1. Chapter Overview10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases10.2.1. Analysis by Year of Utilization10.2.2. Analysis by User's Focus Area10.2.3. Analysis by Type of Software Solution10.2.4. Most Active Players: Analysis by Number of Utilization Instances10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS11.1. Chapter Overview11.2. Cell and Advanced Therapies Value Chain11.2. Cell and Advanced Therapies Value Chain: Cost Distribution11.3.1. Donor Eligibility Assessment11.3.2. Sample Collection11.3.3. Manufacturing11.3.4. Logistics11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS12.1. Chapter Overview12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Methodology13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-203013.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-203013.3.2. Cost Saving Potential in Sample Collection, 2019-203013.3.3. Cost Saving Potential in Manufacturing, 2019-203013.3.4. Cost Saving Potential in Logistics, 2019-203013.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST14.1. Chapter Overview14.2. Key Assumptions and Forecast Methodology14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-203014.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-203014.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-203014.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-203014.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-203014.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Thermo Fisher Scientific15.2.1. Company Snapshot15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager15.3. Cell and Gene Therapy Catapult15.3.1. Company Snapshot15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer15.4. McKesson15.4.1. Company Snapshot15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development15.5. TrakCel15.5.1. Company Snapshot15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS16.1. Chapter Overview16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/kw1hkc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Here is the original post:
Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 - GlobeNewswire

Prolotherapy is the use of a solution that helps grow stronger ligaments and tendons. Arthritis is considered a joint problem but the pain from arthritis is often caused by the surrounding soft tissue, which consists of these ligaments and tendons. Because of this, prolotherapy is a great treatment for a wide range of arthritic conditions. If you have arthritis, you have the opportunity to greatly benefit from prolotherapy.

Ligaments hold together bones. Around a joint they blend together to form a joint capsule. Tendons are said to connect muscles to bones, but it is more accurate to say that tendons are the continuation of the muscles that help connect the muscles to bones. This connection helps the muscles move the bones. The problem for both ligaments and tendons is that they do not get much blood flow. The difference in blood flow between the muscles and tendons and ligaments is highlighted by their color differences. Muscles are red with good blood flow, while ligaments and tendons are yellow-white, suggesting poor blood flow. So when they are injured, ligaments and tendons do not heal well. This contrasts with muscle which, when injured, tends to heal very well, often in four to six weeks.

Joint arthritis is thought of as the wearing out of bones that are connected. A common example is the knee joint. An x-ray of knee arthritis shows that the bones are closer together, called joint space narrowing (or on the spine, called disc space narrowing). Also seen on x-rays are bone spurs that grow off the bone. What is not well visualized on x-ray are ligaments and tendons. It is important to understand that loosening of ligaments plays a key role in the development of arthritis. Also, much of the arthritic pain is from the ligaments and tendons around the joint. By strengthening the ligaments and tendons with the prolotherapy solution, the arthritic pain can dramatically improve. Even when knee arthritis is severe, as in bone-on-bone, the pain can improve with prolotherapy. That is because much of the pain is coming from the ligaments and tendons, and even with severe arthritis the tendons and ligaments respond well to prolotherapy.

As a general rule, bone spurs result from loose ligaments. When a ligament is loose, the joint has intrinsic instability. Sometimes the instability is severe that the joint slips out of place. More often, there is mild laxity (looseness) such that the bones mildly rub against one another. In reaction to this physical stress, bone spurs develop as a way for the bone to protect itself. While the bone spur can cause some stiffness with movement, it usually does not cause pain. However, the unhealthy ligaments can cause significant pain. By improving the strength of the ligament, the joint pain will subside. When joint movement is affected by arthritis, the tendons also bear stress with the abnormal movement. These weakened tendons also produce pain. When the tendons are strengthened, the pain is significantly improved.

The shoulder is the most mobile joint in the body, so it is susceptible to arthritis. While they are considered different conditions, rotator cuff tendonitis and shoulder arthritis result from a similar cause. The rotator cuff is a group of four muscles that wrap around the shoulder like a cuff. By its name you can guess that the rotator cuff helps rotate the shoulder. Just as important, the cuff helps stabilize the shoulder, helps keep the shoulder joint in place when the arm is moving. When the ligaments weaken, this puts stress on the shoulder joint so bone spurs form and arthritis develops. At the same time, when the ligaments weaken, the rotator cuff muscles have to work harder. The cuff muscles then become strained, eventually progressing to a tear. Thus, rotator cuff injuries and arthritis form as part of this process. The good news is that because both problems involve ligament laxity and weak tendons, both conditions respond very well to prolotherapy.

Hips and knees are the key weight bearing joints so they are also vulnerable to arthritis. By strengthening the ligaments and tendons around knees and hips, the pain improves. Hands include our most used joints so they are also very susceptible to arthritis. Because they get so much use, the finger joints become stiff, painful and even deformed. While prolotherapy will not necessarily reverse the deformity, arthritic hand pain responds beautifully to prolotherapy. This is because the hand pain is caused by very small tender ligaments which are strengthened by prolotherapy.

While arthritis in the spine has different names including stenosis, spondylosis, facet syndrome and degenerative disc disease, they all have a similar underlying cause: lax ligaments. Even disc herniations are related to lax ligaments. Discs are sandwiched by the vertebrae (spine bones) and are made of fibrous tissue with a central gel-like substance. When the ligaments weaken, the vertebrae lose their support. This increases disc pressure, so the disc fibers weaken, eventually herniating or falling out. When the disc compresses the nerve, severe leg pain results, otherwise known as sciatica. As the discs wear out, the space between the vertebrae narrows, with bone spurs forming. This leads to the typical arthritic spine pain, known by the various names described above. This process is similar in the cervical spine (neck) and lumbar spine (low back). The key to understanding this is that it is lax ligaments which are a strong contributor to all these conditions. This is why prolotherapy is so effective for neck and back pain conditions.

Another key aspect of prolotherapy that complements its effectiveness is that it is very safe. As opposed to a steroid injection, which suppresses body functions and has to be limited due its toxicity, prolotherapy stimulates the bodys healing reactions so it can be repeated, if necessary, and can be used for multiple areas of pain. As opposed to arthroscopy, which treats arthritic pain by cutting away loose tissue fragments and bone spurs, prolotherapy treats arthritic pain by building and strengthening tissue for long-term healing.

In summary, prolotherapy is a great treatment for arthritis affecting multiple joints, including the most commonly affected joints such as the shoulders, hips, knees and fingers, and even less commonly affected joints such as the elbows, wrists, ankles and toes, and also anywhere along the spine including the neck and low back. The reason it is so effective for arthritis is because the pain caused by arthritis is often caused by lax ligaments and these ligaments are strengthened by prolotherapy. Please check my website where I describe the logistics of prolotherapy (Prolotherapy Info) and go into more detail about how prolotherapy works (How Prolotherapy Works).

Dr. Slaten is a pain wellness physician in Ridgewood. For more than 20 years, he has been practicing with great skill and an open mind. Learn more about prolotherapy and his other treatments at his website, http://www.njprolo.com.

More:
Prolotherapy Is a Great Treatment for Arthritis - Jewish Link of New Jersey

While most polar bears live only to their mid-20s, Boris recently celebrated his 34th birthday, meaning hes probably the oldest male polar bear on the planet, and hes living out his best retirement years at Point Defiance Zoo & Aquarium after living treacherously with a traveling circus.

At 11:01 a.m. on an unseasonably warm morning, Point Defiance Zoo & Aquarium staff biologist Cindy Roberts exited the backstage area of the zoos polar bear exhibit and arrived moments later in the public viewing area for her two furry, white charges.

My name is Cindy, Im a staff biologist, and Im lucky enough to work with our two polar bears, Roberts said with an energetic smile as she addressed the families that had accumulated in front of the exhibit.

We have Blizzard, who is our younger bear; he is going to be 24 years old, Roberts continued. And we also have Boris, who is our really old bear; he (turned) 34 on Dec. 15th.

Blizzard was standing just beyond the exhibits saltwater pool. Elsewhere, hidden from the view of the crowd, Boris lounged indoors with his hind legs spread straight out behind him as he laid on the floor and pawed languidly at an ice treat fillets of salmon in a block of ice in front of him.

The 873-pound-bear is perfectly content, and despite some common elderly issues skin and liver problems, arthritis, and bad teeth from years of mistreatment hes living a happy, healthy life.

Prior to coming to Point Defiance in the early aughts, Boris lived a storied life with two circus productions. He was born in a German zoo in the mid-1980s, and at 18 months old, started performing with Ursula Bttcher, one of the most celebrated female animal trainers in the world, who was particularly famous for performances with polar bears.

She took care of those bears very well for that time period, Roberts said of the research shed done on Bttcher and her act. If she thought anyone was harming them in any way, she would fire them instantly.

However, after the fall of the Berlin Wall and the unification of Germany in 1989, the state-run East German circus that effectively owned Boris began to be phased out, and by the late 1990s, the bears had been sold. Some remained in Europe, but most were sold to the Suarez Brothers Circus in Mexico.

The Suarez Brothers badly mistreated the bears, feeding them a feeble diet of bread and lettuce and housing them in small cages without room to swim or cool off. The bears were eventually seized by American authorities after the zoo traveled to Puerto Rico a U.S. territory.

A YouTube video taken around the time of the bears seizure shows the massive mammals crammed into small cages atop a trailer. The bears were panting, drooling, and swaying side to side in an attempt to cool themselves.

Our vet at the time, Dr. Holly Reed she has since passed away she actually transported the bears to the U.S., and they were in pretty bad shape, Roberts said. We got Boris and Kenny the other bears went to Baltimore, Detroit, and North Carolina.

Though Roberts was not at the zoo when Boris arrived, she has now worked with him for more than a decade, and he holds a special place in her heart.

Hes just an amazing animal because of his history, she said. I think not only does (his story) give us all passion for polar bears in general, but it gives us hope in facing challenges and getting to the other side where you get salmon treats and you dont have to go outside.

Born: Dec. 15, 1985

Weight: 873 pounds

Height: 5 feet

Diet: Raw ground meat, fish, beef fat, and specially formulated kibble

Pounds of food per day: 7.5 to 21

Medication: 134 pills a day

Fun fact: He was the first polar bear to receive a stem cell transplant, to help lessen the effects of his arthritis.

Save the date

Interested in learning about how to help polar bears like Boris live long, healthy lives? Consider attending the zoos annual Party for Polar Bears, presented by the Point Defiance Chapter of the American Association of Zookeepers from 5 to 9 p.m. on Feb. 24, at Dystopian State Brewing in Tacoma. More information here.

Originally posted here:
The Oldest Polar Bear in the World Likely Lives in Tacoma - 425magazine.com

The report titled Global Psoriatic Arthritis Treatment Market Size, Status and Forecast 2019-2025 provide (6 Year Forecast 2019-2025)enhanced on worldwide competition by topmost prime companies (Eli Lilly, Roche, Merck, Novartis, Abbvie, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen, Valeant Pharmaceuticals) which providing information such asCompany Profiles, Capacity, Gross, Gross Margin, Product Picture and Specification, Production, Price, Cost, Revenueand contact information. This Psoriatic Arthritis Treatment market report crucial insights that facilitate theMarket Trends, Drivers, Market Dynamics, Overview, Scope, Definitions, Classifications, Opportunities, Competitive Landscape. The report provides key statistics on the market status of the Psoriatic Arthritis Treatment market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Get Free Sample PDF (including full TOC, Tables and Figures)of Psoriatic Arthritis Treatment [emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2237281

Target Audience of Psoriatic Arthritis Treatment Market :Key Consulting Companies & Advisors, Production Companies, Suppliers,Channel Partners, Marketing Authorities, Subject Matter Experts,Research Institutions, Financial Institutions,Market Consultants, Equipment Suppliers/ Buyers, Industry Investors/Investment Bankers Government Authorities.

Scope of Psoriatic Arthritis Treatment Market:The report affords a basic outline of the Psoriatic Arthritis Treatment Market report contains definitions, competitive landscape evaluation, segmentations, applications, key providers, market drivers and challenges. The Psoriatic Arthritis Treatment Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Kits Reagents Instruments

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Psoriatic Arthritis Treatment market for each application, including-

Hospitals Clinics Ambulatory Surgery Centers Diagnostic Laboratories

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2237281

Psoriatic Arthritis Treatment Market: Regional Analysis Includes:

The Psoriatic Arthritis Treatment Market Report Can Answer The Following Questions:

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Psoriatic Arthritis Treatment market?

Who are the key manufacturers of Psoriatic Arthritis Treatment market? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the upstream raw materials and manufacturing equipment of Psoriatic Arthritis Treatment? What is the manufacturing process of Psoriatic Arthritis Treatment?

Economic impact on Psoriatic Arthritis Treatment industry and development trend of Psoriatic Arthritis Treatment industry.

What will the Psoriatic Arthritis Treatment market size and the growth rate be in 2025?

What are the key market trends impacting the growth of the Psoriatic Arthritis Treatment market?

What are the Psoriatic Arthritis Treatment market challenges to market growth?

What are the Psoriatic Arthritis Treatment market opportunities and threats faced by the vendors in the Psoriatic Arthritis Treatment market? Etc.

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

This post was originally published on Market Research Sheets

See the rest here:
Psoriatic Arthritis Treatment Market Advance Technology And New Innovations 2020 To 2025 -Eli Lilly, Roche, Merck, Novartis - Market Research Sheets